1003 related articles for article (PubMed ID: 17697728)
21. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
22. [Significance of CEA, SCC and Cyfra21-1 serum test in esophageal cancer].
Mao YS; Zhang DC; Zhao XH; Wang LJ; Qi J; Li XX
Zhonghua Zhong Liu Za Zhi; 2003 Sep; 25(5):457-60. PubMed ID: 14575569
[TBL] [Abstract][Full Text] [Related]
23. The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer.
Ando S; Suzuki M; Yamamoto N; Iida T; Kimura H
Anticancer Res; 2004; 24(3b):1941-6. PubMed ID: 15274381
[TBL] [Abstract][Full Text] [Related]
24. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
[TBL] [Abstract][Full Text] [Related]
25. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC).
Cedrés S; Nuñez I; Longo M; Martinez P; Checa E; Torrejón D; Felip E
Clin Lung Cancer; 2011 May; 12(3):172-9. PubMed ID: 21663860
[TBL] [Abstract][Full Text] [Related]
26. [Usefulness of CYFRA21-1 as a tumor marker of non-small-cell lung cancer].
Tan Y; Zhang P; Zheng C
Zhonghua Zhong Liu Za Zhi; 1999 Jul; 21(4):287-9. PubMed ID: 11776818
[TBL] [Abstract][Full Text] [Related]
27. [Detection and diagnostic value of serum carcinoembryonic antigen and cytokeratin 19 fragment in lung cancer patients].
Hang ZQ; Zheng MF; Huang JH
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):847-9. PubMed ID: 22335951
[TBL] [Abstract][Full Text] [Related]
28. Serum sialyl lewis X-i antigen levels in non-small cell lung cancer: correlation with distant metastasis and survival.
Satoh H; Ishikawa H; Kamma H; Yamashita YT; Takahashi H; Ohtsuka M; Hasegawa S
Clin Cancer Res; 1997 Apr; 3(4):495-9. PubMed ID: 9815711
[TBL] [Abstract][Full Text] [Related]
29. Predictive value of preoperative serum sialyl Lewis X-i antigen levels in non-small cell lung cancer.
Satoh H; Ishikawa H; Yamashita YT; Takahashi H; Ishikawa S; Kamma H; Ohtsuka M; Hasegawa S
Anticancer Res; 1998; 18(4B):2865-8. PubMed ID: 9713476
[TBL] [Abstract][Full Text] [Related]
30. Positive reactions for both Cyfra21-1 and CA125 indicate worst prognosis in non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Yamamoto N; Iida T
Anticancer Res; 2003; 23(3C):2869-74. PubMed ID: 12926125
[TBL] [Abstract][Full Text] [Related]
31. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma.
Okada M; Nishio W; Sakamoto T; Uchino K; Yuki T; Nakagawa A; Tsubota N
Ann Thorac Surg; 2004 Sep; 78(3):1004-9; discussion 1009-10. PubMed ID: 15337038
[TBL] [Abstract][Full Text] [Related]
32. A case-case study comparing the usefulness of serum trace elements (Cu, Zn and Se) and tumor markers (CEA, SCC and SLX) in non-small cell lung cancer patients.
Oyama T; Kawamoto T; Matsuno K; Osaki T; Matsumoto A; Isse T; Nakata S; Ozaki S; Sugaya M; Yasuda M; Yamashita T; Takenoyama M; Sugio K; Yasumoto K
Anticancer Res; 2003; 23(1B):605-12. PubMed ID: 12680155
[TBL] [Abstract][Full Text] [Related]
33. Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer.
Nieder C; Andratschke N; Jeremic B; Molls M
Anticancer Res; 2003; 23(6D):5117-23. PubMed ID: 14981976
[TBL] [Abstract][Full Text] [Related]
34. Pathologic stage I non-small cell lung cancer with high levels of preoperative serum carcinoembryonic antigen: clinicopathologic characteristics and prognosis.
Matsuguma H; Nakahara R; Igarashi S; Ishikawa Y; Suzuki H; Miyazawa N; Honjo S; Yokoi K
J Thorac Cardiovasc Surg; 2008 Jan; 135(1):44-9. PubMed ID: 18179917
[TBL] [Abstract][Full Text] [Related]
35. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor.
Kaminska J; Kowalska M; Kotowicz B; Fuksiewicz M; Glogowski M; Wojcik E; Chechlinska M; Steffen J
Oncology; 2006; 70(2):115-25. PubMed ID: 16645324
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer.
Nisman B; Amir G; Lafair J; Heching N; Lyass O; Peretz T; Barak V
Anticancer Res; 1999; 19(4C):3549-52. PubMed ID: 10629651
[TBL] [Abstract][Full Text] [Related]
37. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
[TBL] [Abstract][Full Text] [Related]
38. Tumor markers as prognostic factors in treated non-small cell lung cancer.
Trapé J; Buxo J; Pérez de Olaguer J; Vidal C
Anticancer Res; 2003; 23(5b):4277-81. PubMed ID: 14666638
[TBL] [Abstract][Full Text] [Related]
39. Persistently high serum carcinoembryonic antigen levels after surgery indicate poor prognosis in patients with stage I non-small-cell lung cancer.
Wang CY; Huang MS; Huang MH; Lee HC; Hsu HS
J Surg Res; 2010 Oct; 163(2):e45-50. PubMed ID: 20638687
[TBL] [Abstract][Full Text] [Related]
40. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]